Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 7,500 Shares

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 7,500 shares of the company’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $13.72, for a total value of $102,900.00. Following the completion of the transaction, the director now directly owns 69,260 shares of the company’s stock, valued at approximately $950,247.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Novavax Stock Performance

Shares of NASDAQ:NVAX opened at $13.96 on Monday. The business has a 50 day simple moving average of $11.04 and a two-hundred day simple moving average of $6.94. Novavax, Inc. has a 1 year low of $3.53 and a 1 year high of $23.86.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.01). The company had revenue of $93.90 million during the quarter, compared to the consensus estimate of $71.32 million. During the same period in the prior year, the firm posted ($3.41) EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. As a group, equities research analysts predict that Novavax, Inc. will post 0.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NVAX. Edgestream Partners L.P. boosted its position in Novavax by 23.7% in the 1st quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 2,447 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Novavax by 31.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 11,298 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 2,711 shares during the period. Swedbank AB bought a new position in shares of Novavax during the 1st quarter worth $26,000. Tower Research Capital LLC TRC increased its stake in shares of Novavax by 102.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 13,944 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 7,072 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Novavax by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 56,065 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 8,128 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Bank of America increased their price objective on shares of Novavax from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, June 14th. JPMorgan Chase & Co. upgraded Novavax from an “underweight” rating to a “neutral” rating in a research report on Friday, May 10th. TD Cowen boosted their target price on Novavax from $5.00 to $10.00 and gave the stock a “hold” rating in a research report on Monday, May 13th. B. Riley raised their price target on Novavax from $11.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research note on Monday, May 13th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $19.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.